31 Results for "

reader

" in MedChemExpress (MCE) Product Catalog:
Products (31)

31 Results for "reader" in MCE Product Catalog:

Cat. No.: HY-142952
Research Areas:  

Cancer

UNC6864 (Kei), an ethylisopropyllysine (Kei)-containing ligand, binds to wild-type CBX5, with a KD of 3.3 μM .
loading...
    loading...
Cat. No.: HY-142953
Research Areas:  

Cancer

UNC6349 (Ket2), a diethyllysine (Ket2)-containing ligand, binds to wild-type CBX5, with a KD of 3.2 μM .
loading...
    loading...
Cat. No.: HY-142954
Research Areas:  

Cancer

UNC6212 (Kme2), a dimethyllysine (Kme2)-containing ligand, has a KD for CBX5 of 5.7 μM .
loading...
    loading...
Cat. No.: HY-161670
Research Areas:  

Cancer

NSD2-PWWP1 ligand 1 (compound 34) is a small molecule ligand targeting the NSD2-PWWP1 domain (pIC50: 8.2). NSD2 is a large multidomain protein with histone writer and histone reader functions. Dysregulation of the levels of histone methyltransferase nuclear receptor binding SET domain 2 (NSD2) may lead to a variety of hematological and solid malignancies. NSD2-PWWP1 ligand 1 binds to NSD2, reducing its enzymatic activity and inhibiting tumorigenesis .
loading...
    loading...
Cat. No.: HY-D2422C
Research Areas:  

Cancer

Cy5-Paclitaxel bromide is a fluorescently labeled drug probe formed by conjugating the fluorescent dye Cy5 (Cyanine 5) with the chemotherapeutic agent Paclitaxel, which is used to track the cellular uptake, subcellular distribution and drug delivery process of Paclitaxel. The Cy5 (Cyanine 5) fluorophore is covalently linked to Paclitaxel, possessing both fluorescent tracing function and the biological activities of Paclitaxel (promoting tubulin polymerization and arresting the cell cycle at the G2/M phase); after entering cells, Cy5 emits far-red fluorescence, enabling real-time monitoring of drug localization and release .
loading...
    loading...
Cat. No.: HY-181065
CAS No.: 3099617-79-2
Research Areas:  

Cancer

LS-170 is a YEATS2 YEATS domain inhibitor with an IC50 of 0.14 μM. LS-170 displays selectivity for the YEATS2 YEATS domain over other YEATS domain family members and other epigenetic 'reader' and 'eraser' proteins. LS-170 reduces chromatin occupancy of the Ada-two-A-containing (ATAC) complex, decreases ATAC-dependent histone acetylation levels, and downregulates expression of ATAC-governed genes. LS-170 suppresses tumor growth in a lung cancer mouse model. LS-170 can be used for the research of non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-L024
931 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 931 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

Cat. No.: HY-P701613
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CECR2; Cat Eye Syndrome Chromosome Region, Candidate 2; CECR2 Histone Acetyl-Lysine reader; Cat Eye Syndrome Critical Region Protein 2; Chromatin Remodeling Regulator CECR2; Alternative Protein CECR2; KIAA1740
Species:  
Human
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-10898R
CAS No.: 483313-22-0
SB-674042 (Standard) is the analytical standard of SB-674042 (HY-10898). This product is intended for research and analytical applications. SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd=5.03 nM), exhibits 100-fold selectivity for OX1 over OX2 receptors with IC50 values of 3.76 nM and 531 nM, respectively .
loading...
    loading...
Cat. No.: HY-L005M
295 compounds

Epigenetics involves heritable phenotypic changes that occur without alterations to the underlying DNA sequence. Key mechanisms include DNA methylation, histone modifications, and regulation by small non-coding RNAs such as microRNAs. By modifying DNA, histones, or RNA—while leaving their primary sequences intact—these processes influence molecular function and regulation, thereby playing critical roles in cellular differentiation, embryonic development, gene expression control, aging, and diseases such as cancer.

MCE provide a unique collection of 295 epigenetics-related compounds. For each regulatory target and its subtype, 3 to 5 highly specific representative compounds have been retained, which can be used in epigenetic and related disease research.

Cat. No.: HY-L005
2,031 compounds

Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases.

MCE provide a unique collection of 2,031 epigenetics-related compounds that can be used in the research of the related diseases.